SNGX Stock: The Big FDA News Giving Biotech Penny Stock Soligenix a Boost

Soligenix (NASDAQ:SNGX) stock is roaring higher on Thursday thanks to some positive news from the U.S. Food and Drug Administration (FDA) today.

colorful pills and vials sitting on a table representing SNGX stock.

Source: Bukhta Yurii /

The run for SNGX stock has to do with the FDA’s Office of Orphan Products Development of the United States granting it orphan drug designation. This is for the active ingredient hypericin and its use in treating T-cell lymphoma.

The FDA’s decision today is an expansion on previous orphan drug designation for hypericin. That allowed it to be used in the treatment of cutaneous T-cell lymphoma.

That’s great news for SNGX shareholders as it opens the drug up to a wider market. In addition to this, it also gives it other advantages. Among them are seven-year market exclusivity after final approval, as well as financial and regulatory benefits including government grants covering clinical trials and waiving FDA user fees.

Christopher Schaber, PhD, president and CEO of Soligenix, said the following about the news sending SNGX stock higher.

“The FDA’s decision to grant and expand our hypericin orphan drug designation beyond CTCL signifies an important step for Soligenix as we continue to advance the program toward NDA filing in the first half of 2022.”

SNGX is seeing heavy trading on the FDA news today. As of this writing, some 42 million shares of the stock have changed hands. That’s a massive surge compared to the company’s daily average trading volume of about 678,000 shares.

SNGX stock was up 9% as of Thursday afternoon.

There’s more hot stock market coverage worth checking out below!

InvestorPlace has traders covered with all of the latest stock news they need to know about. That includes the latest concerning Jaguar Health (NASDAQ:JAGX), Torrid (NYSE:CURV), and Hyzon Motors (NASDAQ:HYZN) today. You can see what has these stocks on the move at the following links!

More Thursday Stock Market News

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed

Article printed from InvestorPlace Media,

©2022 InvestorPlace Media, LLC